Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
18 stopped studies mapped to Malignant Retroperitoneal Neoplasm and descendants · 94% state a reason
Over the 18 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant…(Spencer) | Phase 1 / Phase 2 | terminated | Dec 5, 2019 | Enterome | Strategic decision | Sponsor / business decision |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With… | Phase 2 | terminated | Dec 2, 2022 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | Phase 1 | terminated | Aug 21, 2023 | Radionetics Oncology | Sponsor decision | Sponsor / business decision |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | Phase 2 | withdrawn | Dec 30, 2021 | David Liebner, MD | PI decision | Other (stated, no rule matched) |
| NCT04447014 | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | — | terminated | Jun 25, 2020 | National Cancer Institute (NCI) | To avoid the duplication of resources and effort associated with the PI switching branches. | Other (stated, no rule matched) |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | Phase 2 | withdrawn | Mar 31, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | withdrawn by PI | Other (stated, no rule matched) |
| NCT01086696 | A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors… | Early Phase 1 | terminated | Mar 15, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Phase 2 | terminated | Mar 28, 2016 | Northwestern University | Study did not meet first stage requirements of interim analysis | Efficacy / futility |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow enrollment | Enrollment / accrual |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT00901836 | Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma(SA03) | N/A | terminated | May 14, 2009 | University of Florida | Study closed due to feasability | Other (stated, no rule matched) |
| NCT01832974 | Possible New Therapy for Advanced Cancer | Phase 1 | terminated | Apr 16, 2013 | INSYS Therapeutics Inc | Business decision by the sponsor during Phase 1. | Sponsor / business decision |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | Phase 2 | withdrawn | May 4, 2007 | Dartmouth-Hitchcock Medical Center | unable to enroll subjects into the study | Enrollment / accrual |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That… | Phase 2 | terminated | Oct 23, 2008 | National Cancer Institute (NCI) | The trial was permanently halted due to futility concerns. | Efficacy / futility |
| NCT00002921 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer… | Phase 2 | terminated | Jul 30, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Lack of Accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 3, 2026source: clinicaltrials